AS703569 Phase I in Patients With Solid Tumours

Phase 1 Completed 104 enrolled EMD Serono

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Timeline

Start: 2006-08
Primary completion: 2010-06
Completion: 2010-06

Publications

Results Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	CENISERTIB	Small molecule	2 mg/m2	Oral
Comparator	CENISERTIB	Small molecule	3 mg/m2	Oral
Comparator	CENISERTIB	Small molecule	10 mg/m2	Oral

AS703569 Phase I in Patients With Solid Tumours

Summary

Timeline

Publications

Drugs

Indications